TuHURA Biosciences Outlines Development Pathway For Single Phase 3 Accelerated Approval Registration Trial
TuHURA Biosciences Outlines Development Pathway For Single Phase 3 Accelerated Approval Registration Trial
IFx-2.0, a first-in-class innate immune response agonist, entering single Phase 3 accelerated approval registration trial in first half of 2025 for first line treatment of Merkel Cell Carcinoma (MCC) under Special Protocol Assessment (SPA) agreement with U.S. Food and Drug Administration (FDA)
IFx-2.0，首款內源性免疫應答激動劑，將於2025年上半年進入單一3期加速審批註冊試驗，用於梅克爾細胞癌（MCC）的一線治療，並與美國食品和藥物管理局（FDA）簽訂特殊方案評估（SPA）協議。
Entered into a non-binding letter of intent with Kineta regarding a potential transaction in which TuHURA would acquire the rights to KVA12123 expanding its pipeline with a Phase 2 ready, novel VISTA inhibiting antibody
與Kineta達成了一份非約束性的意向書，涉及TuHURA可能收購KVA12123的權利，從而擴展其管線，增加一款準備進入2期的、創新的VISTA抑制抗體。
Advancing IFx-3.0, the first systemically administered tumor-targeted mRNA innate immune response agonist for aggressive B Cell Lymphoma
推進IFx-3.0，首個系統性給藥的腫瘤靶向mRNA內源性免疫應答激動劑，用於治療侵襲性的B細胞淋巴瘤。
Early discovery programs designing first-in-class tumor microenvironment modulating bi-specific antibody drug conjugates (ADCs) or peptide drug conjugates (PDCs) targeting Myeloid Derived Suppressor Cells (MDSCs)
早期研發項目設計首款腫瘤微環境調節雙特異性抗體藥物偶聯物（ADCs）或肽藥物偶聯物（PDCs），針對髓源抑制細胞（MDSCs）。
Company expands leadership team with key clinical and regulatory appointments to drive strategy and operational execution
公司通過關鍵的臨床和監管任命擴大領導團隊，以推動策略和運營的執行。
譯文內容由第三人軟體翻譯。
